KJ
Knight Jeff E.
首席执行官
C-suiteM
内部人交易记录
首席执行官尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the full record of transactions filed by Knight Jeff E., 首席执行官. Insider active across 1 company, notably Crinetics Pharmaceuticals, Inc.. Cumulatively, 18 reports have been recorded. Split: 0 buy · 5 sells. Total volume traded: €3.4m. History available since 28 February 2022. The latest transaction was disclosed on 8 April 2026 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Knight Jeff E.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
85,163 股@ US$40.1049.3% 占其流量Common StockSEC:0001628280-26-024716:3
49,474 股@ US$23.9817.1% 占其流量Common StockSEC:0001628280-26-024716:0
9,624 股@ US$20.022.8% 占其流量Common StockSEC:0001628280-26-024716:1
19,336 股@ US$19.645.5% 占其流量Common StockSEC:0001628280-26-024716:2
5,950 股@ US$37.113.1% 占其流量Common StockSEC:0001628280-26-019503:0
34,000 股0Common StockSEC:0001628280-26-011723:0
6,801 股@ US$34.1714.1% 占其流量Common StockSEC:0000950170-25-043404:0
43,000 股0Common StockSEC:0000950170-25-025666:0
501 股@ US$56.521.8% 占其流量Common StockSEC:0000950170-24-131064:0
17,499 股@ US$23.9825.6% 占其流量Common StockSEC:0000950170-24-084346:0
956 股@ US$44.382.6% 占其流量Common StockSEC:0000950170-24-079152:0
30,000 股@ US$23.9844.0% 占其流量Common StockSEC:0001209191-24-005081:0
4,283 股@ US$38.1410.0% 占其流量Common StockSEC:0001209191-24-005012:0
23,000 股0Common StockSEC:0001209191-24-004606:0
587 股@ US$17.120.6% 占其流量Common StockSEC:0001209191-23-019768:0
29,500 股0Common StockSEC:0001209191-23-015556:0
1,152 股@ US$17.441.3% 占其流量Common StockSEC:0001209191-22-043524:0
4,950 股0Common StockSEC:0001209191-22-015133:0
About Knight Jeff E.
Jeff E. Knight is Directeur Général and has filed 18 disclosures in total. Across the 18 sampled recent filings between 2022-03-02 and 2026-04-10, the reported sell amount totals EUR 3401307 and the most frequent transaction nature is Levée d'options. He is also listed as Chief Dev. & Operating Officer at Crinetics Pharmaceuticals, Inc. (XNAS).